Publications by authors named "Viktor Kibanov Solomonov"
Article Synopsis
- * Patients received either 600 U or 800 U of aboBoNT-A, or a placebo, and significant reductions in NDOI episodes per week were observed at week 6 for both treatment groups compared to placebo (p < 0.001).
- * Improvements in urinary incontinence and quality of life were notable, with about one-third of patients in the treatment groups experiencing no NDOI episodes, while the most common side effect was symptomatic urinary tract infection. *
To evaluate the clinical safety profile for the use of gold nanoshells in patients with human prostate cancer. This follows on the nonclinical safety assessment of the AuroShell particles reported previously. Twenty-two patients, with biopsy diagnosed prostate cancer, underwent nanoshell infusion and subsequent radical prostatectomy (RRP).
View Article and Find Full Text PDF